Tamas Koncz, MD, MSc, Ph.D., is Chief Medical Officer (CMO) for the Inflammation and Immunology (I&I) Business at Pfizer. As CMO, Tamas leads the medical affairs organization, medical professionals across the world who are responsible for ensuring the safe and effective use of Pfizer I&I medicines, as well as continuous data generation and dissemination to advance the understanding of the medicines’ benefit: risk profiles. Medical affair colleagues are also involved in projects supporting research and early and late phase development, regulatory affairs, reimbursement and lifecycle management of the medicines. Throughout his career, Tamas has held various roles as a VP Global TA Lead, Global and European Medical Director, UK country medical adviser, health economist working with a broad portfolio and medical devices. Tamas holds an MD from the University of Debrecen, Hungary. Additionally, he completed an MSc in Economics at the Corvinus University, Budapest, an MSc in Health Economics at the University of York, UK and an MSc in Pharmaceutical Medicine at the University of Surrey, UK. Tamas also holds a Ph.D. from Semmelweis University, Hungary.
Greg Christopherson is the Vice President of Medical Affairs for Medline Industries, a privately-owned manufacturer and distributor of medical devices and supplies devoted to the continuum of healthcare. His current role oversees creation and execution of a comprehensive clinical strategy for the company, encompassing: identification of business and regulatory needs (Clinical Affairs), study design and execution (Clinical Operations), communication of clinical results and publication tactics (Medical Communications) and development of clinical research partners, medical education initiatives and coordination of Medical Science Liaisons (Clinical Development).
Prior to joining Medline, Greg served in a scientific affairs capacity for the medical aesthetics division of Allergan, coordinating R&D efforts to commercially support new product launches and the existing device portfolio for breast implants and acellular dermal matrices. He played a key collaborative role internally, integrating divisions across the company (Regulatory, Sales & Marketing, Medical Affairs, R&D) to define and execute research strategy, as well as acting as the primary scientist for KOL engagement and medical education.
His previous experience is heavily centered in R&D, as a postdoctoral fellow in the NIH examining the pathophysiology of heterotopic ossification in blast-injured soldiers at Walter Reed, and as a senior scientist at LifeCell, creating novel tissue-based devices for colorectal and wound healing applications. He received his B.S. in Biomedical Engineering from Michigan Technological University, and his M.S. and Ph.D. in Materials Science & Engineering from Johns Hopkins University.
As the CSL Behring Director of Medical Education and Communications, Leah supports the global team within the Hematology Therapeutic Area. She has over 16 years’ experience in global medical communications and education from both the biotechnology and agency sides. This experience spans a broad range of therapy areas, including oncology, immunology, hematology and others with a significant focus in rare diseases. She has partnered with Medical Affairs and Commercial teams within the pharmaceutical industry to create and execute comprehensive medical communication strategies and educational programming throughout all phases of the product life cycle. Currently, Leah is responsible for providing global guidance in the creation of comprehensive medical education and communication strategies and initiatives for several products. Leah is a graduate of Moravian College and earned an MS in Pharmacology from the University of Pennsylvania. Prior to joining the CSL Behring, she worked in various positions focusing on medical and scientific strategy at the Envision Pharma Group, Biocentric, Inc. and Synergy Medical Education.
Charlotte M. E. Kremer, MD, MBA is formerly the Executive VP and Head of Medical Affairs for Astellas, recently retired. In this role, Dr. Kremer provided leadership for the Medical Affairs organization globally.
Dr. Kremer joined Astellas in 2012 with 20 years of experience in the pharmaceutical industry. Prior to Astellas, she held the position of Vice President, Therapeutic Area Head for Ophthalmology, PVD, Rare Diseases and Neuroscience at Pfizer. While at Pfizer, she successfully led and executed the clinical development and global medical programs in these respective areas. Prior to joining Pfizer, Dr. Kremer held positions of increasing responsibility providing medical support, developing Phase 3b/4 clinical trials, and initiating and directing a Medical Liaison program at Organon Pharmaceuticals, both in the Netherlands and in the United States. A native of the Netherlands, Dr. Kremer received her medical degree from the University of Utrecht, The Netherlands. She went on to receive her Diploma Pharmaceutical Medicine (DPM) from Universite Libre de Bruxelles. After transferring to the United States, Dr. Kremer completed the Executive MBA program at New York University’s Leonard N. Stern School of Business.
Faisal joined BMS in July 2016 initially to lead the UK and Ireland Medical organisation, and is now Head of the European Medical group.
He has held a variety of senior leadership roles, most recently at Novartis in the USA, where he was the Vice President of US Clinical Development and Medical Affairs Oncology. Previously he was at GSK, where he was Head of the USA North American Medical Affairs/Clinical Development group for Oncology & Haematology and prior to this he held several roles of increasing seniority at GSK in the UK and at Sanofi in the UK and Paris, France (corporate).
He has extensive experience in late phase drug development, interaction with regulators, HTA bodies and academic co-operative groups globally over 15 years in a variety of therapeutic areas.
Faisal graduated in Medicine from Cambridge University, and before his time in industry, was a practicing physician in the UK in general medicine and oncology.
Shaji Kalathil is currently the Executive Director, Head of IT for Global Medical Affairs and Hematology & Cell Therapy Medical Affairs at Bristol-Myers Squibb (BMS), having global responsibilities for all digital capabilities and services across Medical Affairs. Shaji is well recognized as a leader in driving digital transformation programs and has extensive experience in developing and executing technology vision and strategies at the domestic and global levels with specific focus on Medical Affairs, Commercial, Pharmacovigilance and Regulatory Affairs functions. Prior to joining BMS, Shaji worked at Novartis Pharmaceuticals for 13 years in various IT leadership roles. His last role with Novartis was as the Executive Director, Head of IT Strategy, Innovation & Enabling Technologies where he was responsible for leading digital innovation programs in Medical Affairs and Commercial. Shaji is a computer engineer by profession and prior to Novartis, he worked in the financial services sector leading teams to develop securities trading and clearance systems.